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Abstract
Background: The incidence and morbidity of wheezing illnesses and childhood asthma is especially high in poor
urban areas. This paper describes the study design, methods, and population of the Urban Environment and
Childhood Asthma (URECA) study, which was established to investigate the immunologic causes of asthma among
inner-city children.
Methods and Results: URECA is an observational prospective study that enrolled pregnant women in central
urban areas of Baltimore, Boston, New York City, and St. Louis and is following their offspring from birth through
age 7 years. The birth cohort consists of 560 inner-city children who have at least one parent with an allergic
disease or asthma, and all families live in areas in which at least 20% of the population has incomes below the
poverty line. In addition, 49 inner-city children with no parental history of allergies or asthma were enrolled. The
primary hypothesis is that specific urban exposures in early life promote a unique pattern of immune development
(impaired antiviral and increased Th2 responses) that increases the risk of recurrent wheezing and allergic
sensitization in early childhood, and of asthma by age 7 years. To track immune development, cytokine responses
of blood mononuclear cells stimulated ex vivo are measured at birth and then annually. Environmental assessments
include allergen and endotoxin levels in house dust, pre- and postnatal maternal stress, and indoor air nicotine
and nitrogen dioxide. Nasal mucous samples are collected from the children during respiratory illnesses and
analyzed for respiratory viruses. The complex interactions between environmental exposures and immune
development will be assessed with respect to recurrent wheeze at age 3 years and asthma at age 7 years.
Conclusion: The overall goal of the URECA study is to develop a better understanding of how specific urban
exposures affect immune development to promote wheezing illnesses and asthma.
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Background
With 22 million current asthmatics in the U.S., including
6.5 million children, asthma is a significant public health
problem [1]. The problem is even more significant among
children and adults living in the inner city, where asthma
prevalence, morbidity, and mortality rates are much
higher than overall U.S. rates [2-4]. Many inner-city pop-
ulations are characterized by low socioeconomic status
(SES), and indicators of low SES, such as low family
income, low education level, and residence in a high pov-
erty area, are associated with an increased asthma preva-
lence [5]. Furthermore, urban populations are enriched
for minorities, and in the United States minority popula-
tions are about 20% more likely to have asthma than
whites [1]. However, much of the increased asthma risk
attributed to race, ethnicity, or SES is likely due to envi-
ronmental exposures [6]. The urban environment
presents a unique collection of potentially harmful expo-
sures, such as rodent and cockroach allergens, air pollu-
tion, stressful life events, infections, and microbial
exposures. Although much has been learned recently
about the effects of allergen exposures on asthma morbid-
ity among inner-city children [7-9], there is relatively little
information about the role allergens and other environ-
mental exposures play in the initiation of asthma among
these children.
Key to understanding the role of environmental exposures
in the development and exacerbation of asthma and other
allergic diseases is to determine how those exposures
affect immune development, not only during early child-
hood, but during fetal life. Allergic disease has been attrib-
uted to an imbalance between Th1 and Th2 patterns of
cytokine release, and although the simplicity of that para-
digm has been brought into question, there is increasing
evidence that allergy and asthma are associated with
abnormal patterns of cytokine secretion [10,11]. For
example, newborns that go on to develop recurrent
wheezing and/or atopy have a distinct pattern of immune
responses at birth or in early infancy. The observed abnor-
malities include diminished IFN-J production, [12,13]
and surprisingly, reduced Th2 responses as well [13-15].
However, the first few years of life are associated with pro-
nounced maturational changes in cytokine responses, and
atopy is associated with a progressive skewing of immune
responses to allergen (and perhaps to other stimuli)
towards a Th2 phenotype [16,17]. Although genetic fac-
tors contribute to this altered pattern of immune develop-
ment, there is evidence that environmental exposures
during early infancy help to shape the development of
cytokine responses, [18] and also modify the risk of devel-
oping allergic diseases [17,19]. Furthermore, immuno-
logic responses in early life also affect the risk of
developing wheezing illnesses with viral respiratory infec-
tions [15,20]. Notably, atopic diseases and viral wheezing
illnesses in infancy synergistically increase the risk for sub-
sequent childhood asthma [21,22]. These findings,
together with the observed increased rates of childhood
asthma in urban environments, suggest that: 1) adverse
environmental factors in infancy skew the development of
cytokine responses in early life to increase the risk for
wheezing illnesses and atopy in the first few years, and 2)
these effects ultimately promote childhood asthma. One
of the keys to understanding the pathogenesis of asthma
in urban children will be to determine how the unique
pattern of environmental factors in the inner city affects
immune development.
To determine the immunologic and environmental causes
of asthma in inner-city children, the Inner-City Asthma
Consortium established the Urban Environment and
Childhood Asthma (URECA) study, a birth cohort study
that began enrollment in 2005. The Inner-City Asthma
Consortium, which is sponsored by the National Institute
of Allergy and Infectious Diseases, is a network estab-
lished to conduct research into the etiology and treatment
of childhood asthma in the inner city. The objective of
this paper is to describe the hypothesis, design and meth-
ods of the URECA study.
Methods
Hypothesis and study objectives
URECA has a two-stage hypothesis (Figure 1). First,
unique environmental exposures in the inner city interact
with genetic factors during the prenatal and postnatal
periods to adversely influence the development of the
innate and adaptive immune systems, increasing the risk
for allergic sensitization and atopic diseases. Second,
immune dysregulation in infancy increases the risk of
developing lower respiratory infections caused by viruses
and perhaps atypical bacteria. Those infections cause air-
way inflammation and structural changes during a partic-
ularly vulnerable period of lung development, leading to
an increased risk of asthma by age 7 years.
The primary objective of URECA is to identify in inner-city
children the immunologic risk factors for the develop-
ment of recurrent wheeze by age 3 years and asthma by
age 7 years. To accomplish this objective, blood mononu-
clear cells from each infant are stimulated ex vivo to meas-
ure cytokine response patterns, and those patterns will be
compared between children with and without recurrent
wheeze at age 3 years and with and without asthma at age
7 years. There are two secondary objectives: 1) to identify
environmental exposures that modify the developmental
pattern of cytokine responses, and 2) to identify the
immunologic correlates of the development of atopic fea-
tures such as total IgE, allergic sensitization, and atopic
dermatitis.
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Study design and population
URECA is an observational birth cohort with planned fol-
low-up through age 7 years. Four research centers (Johns
Hopkins University, Baltimore; Boston University and
Harvard University, Boston; Columbia University and Mt.
Sinai University, New York City; Washington University,
St. Louis) are conducting the study. The Administrative
Center and Core Laboratories are at the University of Wis-
consin-Madison, and Rho Inc. (Chapel Hill, NC) serves as
the Statistical and Clinical Coordinating Center. Women
were recruited during their pregnancies. Family eligibility
required 1) having plans to deliver at an affiliated hospi-
tal; 2) biologic mother or father reporting a history of
asthma, hay fever, or eczema; and 3) residence in specific
urban census tracts in which at least 20% of the popula-
tion had incomes below the poverty level, as defined by
the 2000 U.S. Census.
Newborn eligibility required a gestational age of t 34
weeks and collection of a suitable umbilical cord blood
specimen (t 5 mL). Maternal human immunodeficiency
virus, significant congenital anomalies or infections, intu-
bation or t 4 hours of supplemental oxygen or continu-
ous positive airway pressure for 4 or more days excluded
the infant from the study.
Using the same inclusion and exclusion criteria (apart
from that for history of allergic disease), a smaller com-
parison group of children without a parental history of
asthma, hayfever, or eczema was also enrolled. These indi-
viduals will serve as a reference group to examine the dif-
ferences in immunologic responses and other study
measurements from children with a family history of
allergic disease.
Recruitment and enrollment procedures
Eligible women identified in obstetric clinics were sched-
uled for a prenatal study visit at which informed consent
was obtained and questionnaires were administered.
Enrolled women were contacted by telephone within a
month of the projected delivery date to review study pro-
cedures. Using kits provided by URECA, and following a
standardized protocol, nurses or physicians in the delivery
suites collected the cord blood samples, and URECA staff
transported them to the research center's laboratory.
Study eligibility of the child was determined soon after
delivery. URECA staff visited participating mothers in the
hospital and pediatricians and family physicians for the
newborns were mailed a letter informing them of the
child's participation in the study.
Timeline
Following informed consent, a series of questionnaires
was administered to the mother at the prenatal visit (Table
1). Every 3 months from the child's birth, the child's
mother responds to telephone questionnaires that assess
the child's respiratory and allergy symptoms, medica-
tions, tobacco smoke exposure, and diet. Nine stress-
related questionnaires were administered to the mother at
the prenatal visit and, with the exception of the Pregnancy
Anxiety Scale questionnaire, are being re-administered at
most annual clinic visits. Each year, the child has a clinical
visit at which a physical examination is performed, an
eczema assessment is completed, a blood sample is col-
lected, and bioelectrical impedance is measured to esti-
mate percent body fat. A nasal lavage sample is collected
at years 1, 3, 5 and 7. The mother's blood is collected at
the child's 12-month visit. The child undergoes allergy
skin testing at age 33 months, 5 years, and 7 years and pul-
monary function testing annually starting at age 3 years.
Each year, URECA staff visit the child's home to collect set-
tled dust samples. Airborne nicotine and nitrogen dioxide
(NO2) are measured in the homes at month 3, and at age
4 and 6 years. A home environment questionnaire is
administered at month 3, and annually thereafter.
In addition to these scheduled activities, mothers are
instructed to contact URECA staff whenever their partici-
Hypothesized influence of genetic factors, environmental exposures and low r respiratory infections on the develop-ment of wh ezing a d a thmaFigure 1
Hypothesized influence of genetic factors, environ-
mental exposures and lower respiratory infections on 
the development of wheezing and asthma. Abbrevia-
tions: LRI, lower respiratory infection; RSV, respiratory syn-
cytial viruses; HRV, rhinoviruses.
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Table 1: Data collection schedule, Urban Environment and Childhood Asthma (URECA) Study.
Ongoing Visits Clinic Visits (number represents child's age in months)
Pre 3 QC HV 12 24 33 36 48 60 72 81 84
General Questionnaires
Screening and Eligibility – Mother x
Contact Information x x x x x x x x x X x x
Demographics x x x x x x X x
Socioeconomic status x x x x x x
Mother's Health Questionnaires
Respiratory and Allergy History x x
Smoking History and Alcohol Use x
Child's Health Questionnaires
Respiratory and Allergy Symptoms x x x x x x x x X x x
Child's Sleep Questionnaire x x x x x X x
Medications x x x x x x x x X x x
Diet x x x x x x x x X x x
Respiratory Illness Score Card As often as illness is reported
Stress Assessment Questionnaires
Pregnancy Anxiety Scale x
Edinburgh Postnatal Depression x x x x x x x
Perceived Stress Scale x x x x x x x x x X x x
Difficult Life Circumstances x x x x x x
Neighborhood/Block Conditions x x x x
Neighborhood Violence x x x x x x
Housing Stress x x x x x x
Brief COPE x x x x
Social Supports/Networks x x x x
Study Procedures
Cord blood sample (at birth)
Maternal blood sample x
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pating children experience respiratory symptoms, such as
rhinorrhea, cough, or wheezing. Upon notification of a
child's respiratory illness by a parent, additional informa-
tion on the illness and presence of wheezing is collected.
Nasal lavage specimens are collected when the illness
meets pre-specified criteria that signify moderate to severe
respiratory symptoms.
Collection of blood samples
Umbilical cord blood samples were collected at delivery
and peripheral blood samples are being collected from
mothers and children. An attempt was made to collect 50
mL of cord blood, and at least a 5 mL sample was required
for study entry. The cord blood sample was collected by
needle and heparinized syringe, transferred to 2 polypro-
pylene tubes containing tissue culture medium, and was
kept at room temperature pending processing within 16
hours of collection. Approximately 30 mL of peripheral
blood was collected from the mother at the child's 12-
month clinic visit and 15–20 mL from the child at each
annual clinic visit. These samples are transported to the
center's laboratory on the day of collection and kept at
room temperature. At the center-specific laboratories,
blood mononuclear cells are stimulated and tested for
cytokine responses. Plasma is analyzed at a central labora-
tory for antibodies to allergens and pathogens and for
analytes such as soluble CD14 and cotinine. DNA from
the cord and maternal blood samples is being stored for
genetic studies.
Health outcome assessments
Recurrent wheeze
Recurrent wheeze is defined as at least two episodes of
wheezing during the first three years of life with at least
Child blood sample x x x x x X x
Eczema Area and Severity Index x x x x x x X x
Physical examination x x x x x X x
Nasal lavage sample* x x x x
Allergen skin testing x x x
Spirometry and IOS x x X x
Bronchodilator Reversibility x X x
Methacholine Challenge x
Lung Volume (Plethysmography) x
Exhaled Nitric Oxide x X x
Bioelectrical impedance analysis x x x x x X x
Home Environment Assessment
Household Smoking x x x x x x x x X x
Home Environment Questionnaire x x x x x x X x
Home Environment Observation x
Dust sample collection x x
Airborne nicotine and NO2 x x†
Notes: PN = Prenatal Visit; 3 = 3-month Home Visit; QC = Quarterly Calls (occurring at 6, 9, 15, 18, 21, 27, 30, 39, 42, 45, 51, 54, 57, 63, 66, 69, 
75, 78, and 81 months); HV = Home Visits (occurring once between each yearly clinic visit, except after age 5).
*Also collected during respiratory illnesses
†Collected at 3 months, and at age 4, 5 and 6. At age 5, the collection will occur in the opposite season from the age 4 sample.
Table 1: Data collection schedule, Urban Environment and Childhood Asthma (URECA) Study. (Continued)
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one episode during the third year. The study's primary
source of information on the occurrence and frequency of
wheezing is the Respiratory and Allergy Symptoms ques-
tionnaire which is administered every 3 months. Informa-
tion on wheezing is also collected during phone calls at
the time of illnesses, from records of hospitalizations due
to respiratory illnesses, and from physical examinations at
scheduled study visits.
Asthma
Since there is no universally accepted "gold standard" def-
inition for the diagnosis of asthma in early childhood, we
will consider several outcome measures on a yearly basis
beginning at age 5 years. These will include doctor-diag-
nosed asthma, to establish comparability with other stud-
ies, along with a category for doctor-diagnosed active
asthma that includes activity or controller therapy for
asthma in the past 12 months. In addition, a third defini-
tion for clinical asthma will be developed based solely on
activity or treatment in the past 12 months independent
of doctor diagnosis. Bronchodilator reversibility (yearly
beginning at age 4) and methacholine reactivity (81
month visit) will be analyzed separately as asthma-related
outcomes.
Allergic sensitization
For URECA analyses, allergic sensitization is defined as
the presence of either: 1) one or more positive allergy skin
tests, or 2) one or more positive tests for allergy-specific
IgE. Total serum IgE and atopic dermatitis are other atopic
indicators that will be considered as separate outcomes.
Allergy skin testing
Children undergo prick skin testing at ages 33 months
and 5 and 7 years (Multi-Test II, Lincoln Diagnostics,
Decatur, IL) for the following 14 indoor and outdoor
allergens (Greer Laboratories): Alternaria tenius, American
and German cockroach mix, Aspergillus mix, cat hair, Der-
matophagoides farinae, Dermatophagoides pteronyssinus, dog
epithelia, German cockroach, mouse epithelia, Penicillium
notatum, ragweed mix, rat epithelia, Timothy grass, and
tree pollen (white oak at St. Louis and Baltimore sites;
birch mix at Boston and New York sites). Wheal sizes are
measured after 15 minutes. The wheal's longest length
and width (measured perpendicular to the length at its
midpoint) are measured to the nearest millimeter and
averaged to give a mean wheal size. A positive reaction is
defined as a mean wheal size at least 3 mm larger than the
saline control.
Immunoglobulin E and G
Total and allergen-specific IgE and allergen-specific IgG
antibody are measured annually by fluoroenzyme immu-
noassay (UniCAP, Pharmacia & Upjohn, Diagnostics,
Uppsala, Sweden). The panel of specific IgE antibodies
varies by blood sample: egg white, milk, and peanut for
children's samples; birch or oak, ragweed, and Timothy
grass for maternal samples; and Dermatophagoides farinae,
Dermatophagoides pteronyssinus, dog epithelium, cat dan-
der/epithelium, German cockroach, mouse urine protein,
and Alternaria alternata measured for all samples. Meas-
urement of IgG antibodies to selected allergens will be
performed children's blood samples at age 1, 3, 5 and 7
years.
Atopic dermatitis
Atopic dermatitis is assessed by questionnaire every 3
months by asking if a health care provider ever diagnosed
allergic dermatitis or eczema and whether medication was
prescribed for the condition. In addition, at the 3-month
home visit and the child's annual physical examinations,
a nurse or physician completes the Eczema Area and
Severity Index (EASI) form. The EASI is a 20-item assess-
ment tool that scores the extent and severity of eczema on
the head and neck, upper and lower extremities, and trunk
[23].
Pulmonary function
Lung function is assessed by spirometry and impulse
oscillometry (IOS) annually beginning at age 3 years
(Jaeger MasterScope, VIASYS Healthcare, Höchberg, Ger-
many). IOS only requires the child to perform tidal
breathing and is sometimes easier for young children to
perform than a forced expiration. For each of the two lung
function tests, the goal is to obtain three good quality
maneuvers from a maximum of 8. To maximize the com-
pletion rate for the procedures, children receive training in
spirometry and IOS maneuvers at the 33-month clinic
visit.
Beginning at age 5 years, children perform spirometry
with bronchodilator reversibility and measurement of
exhaled nitric oxide (eNO). Measurement of eNO is
obtained prior to spirometry. Exhaled NO is measured
employing a technique modified after Silkoff et al[24] and
following American Thoracic Society guidelines for eNO
assessment [25]. In brief, this technique utilizes a resistive
device that provides a constant low expiratory flow rate
and ensures velum closure. After completion eNO proce-
dures and spirometry as described above, albuterol via
MDI with spacer is administered, and 15 minutes later the
spirometry and IOS is repeated.
At age 7 years, additional pulmonary function measure-
ments are obtained. Measurements of lung volume are
obtained by plethysmography in each research site's pul-
monary function lab. The procedure is done with the child
sitting in a body box following standardized procedures.
Airway responsiveness is measured by assessing the con-
centration of methacholine required to produce a drop in
BMC Pulmonary Medicine 2009, 9:17 http://www.biomedcentral.com/1471-2466/9/17
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FEV1 of 20% (PC20) after the administration of increasing
concentrations of methacholine using the small volume
nebulizer-tidal breathing technique.
Explanatory variable assessments
Mononuclear cell cytokine production
Cytokine responses to ex vivo exposure to innate and
adaptive immune stimuli are being measured in mononu-
clear cell preparations. Cord blood samples were diluted
1:1 with RPMI 1640 medium and kept at room tempera-
ture pending cell separation. Cryopreservation is not used
because preliminary studies demonstrated significant
effects on cytokine responses [26]. At each research center,
mononuclear cells are incubated in the presence of
medium and specific immune stimulants, or medium
alone (Table 2). After incubation is complete, cell super-
natant fluids are collected, divided into aliquots, frozen at
80°C, and shipped to a central laboratory for analysis.
Supernatants are analyzed for cytokines with a bead-based
multiplex assay (Beadlyte, Upstate Biotechnology, Lake
Placid, NY). Cytokines were selected based on involve-
ment with specific innate and adaptive immune responses
that have been related to allergic inflammation and the
immune response to respiratory viruses (Table 2).
Viral respiratory tract infections
Nasal lavage samples are collected from the children dur-
ing routine clinic visits at years 1, 3, 5, and 7, and during
respiratory illnesses. To collect the sample, a modified
bulb syringe is used to irrigate each nostril with 2 mL of
physiologic saline containing 0.5% gelatin, and the same
syringe is used to gently aspirate the nares. The nasal wash
is expelled into a sterile container and transported on ice
to the laboratory where they are vortexed, divided into
aliquots, and frozen at -80°C. Frozen samples are shipped
to a central diagnostic laboratory where they are analyzed
for respiratory viruses by multiplex polymerase chain
reaction assays (Respiratory Viral Panel, EraGen Bio-
sciences, Madison WI) [27].
Indoor aeroallergens and endotoxin
URECA staff collect settled dust samples from the chil-
dren's homes using a Mitest Dust Collector (Indoor Bio-
technologies, Inc., Charlottesville, VA) and a vacuum
cleaner (Oreck Super-Deluxe Compact Canister, Model
BB870AD, New Orleans, LA). At each home visit, 3 dust
samples are collected: 1) a combined sample from child's
bed and bedroom floor, 2) a solitary sample from the
child's bedroom floor, and 3) a combined sample from
the family room floor and sofa or chair. For the combined
bedroom sample, the bed is vacuumed for a total of 5
minutes (3 minutes for the layers of the bedding and the
child's pillow and 2 minutes for the surface of the mat-
tress) and 2-square meters of the floor along side the bed
are vacuumed for 5 minutes. For the solitary floor sample,
1-square meter of bedroom floor is vacuumed for 5 min-
utes. For the combined family room sample, the chair
where the child usually sits is vacuumed for 3 minutes and
1-square meter of the floor is vacuumed for 2 minutes
[28,29]. After a sample is collected, the dust filter is
removed, placed in an airtight plastic bag, and stored at -
20°C. After having been shipped to a central laboratory,
dust samples are sifted, weighed, and divided into aliq-
uots. One aliquot from each sample is extracted and ana-
lyzed for the allergens Bla g 1 (German cockroach), Can f
1 (dog), Fel d 1 (cat), Der f 1 Dermatophagoides farinae),
Der p 1 (Dermatophagoides pteronyssinus), and Mus m 1
(mouse) by two-site monoclonal antibody ELISA (Indoor
Biotechnologies, Inc., Charlottesville, VA). Another aliq-
uot is analyzed for endotoxin (component of gram nega-
tive bacteria) by the recombinant factor C assay [30] and
for muramic acid (gram positive bacteria) and ergosterol
(fungi) using GC-mass spectroscopy.
Indoor air pollution
At the 3-month home visit, airborne nicotine was meas-
ured with a passive diffusion sampler and NO2 was meas-
ured with a modified diffusion filter sampler (Ogawa
Sampler, Ogawa & Company USA, Inc., Pompano Beach,
FL). Both samplers were placed on a stand in the family
room 36 inches above the floor and at least 1 foot away
Table 2: Stimulants used and cytokines measured in the mononuclear cell assays.
Innate Immune Responses Adaptive Immune Responses
Stimulants Cytokines Stimulants Cytokines
Lipopolysaccharide IFN-D Phytohemagglutinin IFN-J
Polyinosinic-polycytidylic acid IFN-J Cockroach extract IL-10
Peptidoglycan IL-10 Dust mite (D. pteronyssinus) IL-13
CpG IL-12p40 extract IL-4
Respiratory syncytial virus TNF-D Tetanus toxoid IL-5†
Rhinovirus* IL-8 CD3 + CD28 Mab*
Medium alone Medium alone
* Stimulation not conducted on cells from the umbilical cord samples
† Not measured in umbilical cord samples
BMC Pulmonary Medicine 2009, 9:17 http://www.biomedcentral.com/1471-2466/9/17
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from a wall, away from any doors or windows. In a ran-
dom selection of homes, replicate samplers were placed
for quality control. After 14 days, the samplers were
retrieved, sealed, and shipped to a central laboratory for
analysis. These measures are repeated in years 4, 5, and 6,
but in different seasons.
Psychosocial stress
Maternal and family stress is assessed by 7 validated ques-
tionnaires, along with 2 others that measure coping and
social support (Table 1) [31-35]. All of the stress assess-
ment questionnaires were administered prenatally, and
with the exception of the Pregnancy Anxiety Scale ques-
tionnaire, are repeated at each annual clinic visit. The brief
4-item Perceived Stress Scale is repeated every 3 months.
Data management
Study data are managed by the Statistical and Clinical
Coordinating Center (SACCC). Data are transmitted elec-
tronically between the research sites and the SACCC using
a computer-based data management system. At each
center, study information is recorded first on paper study
forms, reviewed for accuracy and completeness, and then
entered into the data management system. Once entered,
the data are transmitted via the internet to a central data-
base that resides on a dedicated server at the SACCC.
Paper-copy study documents will be maintained by the
research center that generated them for at least seven years
following the completion of the study.
Statistical analyses
Sample size estimation
The primary health outcome of the first phase of the study
is recurrent wheeze at age 3 years. The long-term goal of
URECA is to study asthma, and therefore the study was
powered to evaluate risk factors for asthma at age 7. The
study was designed to achieve 90% power (D = 0.05, two
sided) to test for an association between cytokine dysfunc-
tion (Th2-skewed cytokine responses) at age 3 years and
increased risk of asthma at age 7 years while also allowing
for the increased risk associated with viral lower respira-
tory tract infection. Th2 cytokine response was defined as
IL-13 response to cell stimulation with cockroach extract.
For the sample size estimation, the following assumptions
were made: 1) the prevalence of asthma at age 7 years
would be 20%, 2) the prevalence of ever experiencing a
lower respiratory tract infection by age 3 years would be
50% for the study population and 50% per quartile of the
IL-13 distribution, and 3) 40% of the children would be
lost to follow-up. The investigators speculated that the
true odds ratio comparing the odds of asthma with and
without cytokine dysfunction would be at least 2.0. With
those assumptions, the sample size was estimated to be
534, and 560 children of allergic families were enrolled
into the cohort.
For the non-allergic families cohort, the sample size
required to detect a significant difference in cytokine
responses between the two URECA cohorts was estimated.
A previous study found that phytohemagglutinin-induced
IFN-J may be as much as 50% lower among children with
a parental history of allergies [36] The sample size analysis
indicated that such a difference could be detected at t
80% power with 30 children in the non-allergic families
group and 500 children in the allergic families group. To
account for loss to follow-up, the decision was made to
enroll 50–60 children in the non-allergic families cohort,
and 49 children were enrolled.
Quality control and protection of human subjects
Quality control and assurance are provided by each
research center's principal investigator and research coor-
dinator and by the SACCC. Central training on study pro-
cedures described in detail in the Manual of Operations
was held prior to the enrollment of the first participant,
and URECA staff are required to successfully complete
proficiency examinations prior to performing a procedure
on a study participant. For the cell stimulation studies,
inter-laboratory variation is assessed annually by having
the center-specific laboratories assay a standardized blood
sample.
The SACCC performs periodic quality control audits on
the database and generates reports that are sent to the
centers for the resolution of any questionable data entries.
In addition, personnel from the SACCC visit each center
yearly to review all aspects of the data collection and
reporting procedures with the research center's staff. As
part of the quality control policy, the SACCC re-enters
approximately 5% of all data collection forms.
The study received IRB approval at all 4 clinical sites and
the administrative center. An independent Data Safety
and Monitoring Board (DSMB) run by the National Insti-
tutes of Health monitors the study.
Families are compensated for their time, and certain med-
ical test results are provided to them. Families and the
child's physician are notified when the complete blood
count shows values outside the normal range, and the
caretakers are asked to call their pediatrician for further
evaluation. Specific IgE to food allergens (egg white, milk,
and peanut) is evaluated and reported within a month of
the clinic visit. Children whose specific IgE suggests a
likely allergy to one of these foods are referred for evalua-
tion by an allergist.
Although URECA staff do not provide any direct medical
care, each time a mother or caretaker calls to report a res-
piratory illness, coordinators ask questions designed to
assess the severity of the child's illness. One of the follow-
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ing recommendations for health care is given: 1) call 911
or go directly to the ED, 2) make a same-day appointment
with the child's pediatrician, 3) make an appointment to
see the pediatrician with a week, or 4) monitor for wors-
ening symptoms.
Results
Screening, eligibility, and enrollment frequencies
Of the 1850 pregnant women who were screened for the
allergic families cohort, 889 (48.1%) met URECA's eligi-
bility criteria (Figure 2). The most common reasons for
ineligibility were 1) living outside of the center's recruit-
ment area or in an ineligible census tract (48.4% of ineli-
gibles), 2) not meeting the allergic family criterion
(20.4%), and 3) having plans to relocate (7.4%). The vast
majority (87.3%) of eligible women consented to the
study, but some of the consenting women were lost to fol-
low-up prior to delivery. The remaining women delivered
750 children, and 560 (74.6%) of those children, includ-
ing 3 sets of twins, were eligible and enrolled. The most
common reasons for a newborn to be ineligible were 1) a
cord blood sample was not collected (56.8% of ineligi-
bles), 2) delivery in a non-study hospital (16.8%), and 3)
gestational age < 34 weeks (12.6%).
Recruitment of non-allergic families began later than
recruitment of allergic families. In all, 240 pregnant
women were screened for the non-allergic cohort, and of
those, 111 (46.2%) were eligible and 70 (63.1% of the eli-
gible) consented to the study. The consenting women
delivered 68 children, and 49 (72.1%) of those children
were eligible and enrolled.
Mothers and fathers
Characteristics of the parents are shown in Table 3.
Although the majority of the mothers were in their twen-
ties, about 25% were under the age of 20 years. Most
mothers and fathers were black or Hispanic. Over 80% of
the women were not married at the time of interview, and
many had less than a high school education. About two-
thirds of the households contained an adult with a regular
job, but only about one-third of households had an
annual income above $15,000. Eighteen percent of moth-
ers in the allergic cohort and 12% in the non-allergic
cohort reported smoking during pregnancy.
Newborns
Characteristics of the newborns were also similar between
the two cohorts (Table 4). Most newborns were of black
race, and a slight majority was male. The vast majority of
children were born at term or later (37 or more weeks),
and the average birth weight was just over 3200 grams.
About one-third of the deliveries were by Cesarean sec-
tion. The average 5-minute Apgar score was 8.9, and
89.6% of children had 5-minute Apgar scores of 9 or 10
points.
Approximately 60% of the mothers initiated breastfeed-
ing, and 24% of the children in the allergic families cohort
and 28% of the children in the non-allergic cohort were
still being breastfed at 3 months postpartum. Nearly 60%
of the newborns were exposed to tobacco smoke in their
homes during the first months of life.
Atopic risk
Histories of asthma, hay fever, and eczema were very com-
mon among the mothers and fathers, reflecting the inclu-
sion criteria for the main cohort (Table 5). Forty-two
percent of the infants in the allergic cohort were enrolled
on the basis of just a maternal history of allergic disease,
but in 46% both parents had some kind of atopic condi-
tion or asthma.
Discussion
Birth cohorts in many different geographic areas have
greatly added to our understanding about the early life
origins of asthma. Investigators have followed a number
of birth cohorts since the latter part of the 20th century to
try to define the causes for the increase in asthma, includ-
ing at least 18 cohorts in Europe alone [37]. In the U.S.
asthma-related birth cohort studies have been or are being
conducted in Arizona [38], Wisconsin [39], Detroit [40],
and Massachusetts [41], among others. Some studies have
been population-based, others have focused on high-risk
children [42]. To our knowledge, no previous asthma
birth cohort study has focused on high-risk, urban, low-
income children in a variety of locations.
The URECA study is uniquely poised to add new informa-
tion about how environmental exposures and lifestyles
that are specific to children in low-income areas of the
inner city affect immunologic development and the risk of
developing recurrent wheezing and ultimately asthma.
Recruitment is now completed, and compared to other
birth cohorts, the participants have distinct demographic
features that reflect the urban population. The children
are predominately minorities, and the socioeconomic sta-
tus of their families is very low compared to the U.S. as a
whole. In 2006, 13.4% of U.S. households reported
incomes less than $15,000 [43], compared to about 2/3 of
the URECA families. Furthermore, over 80% of the
URECA women were not married at enrollment and 42%
of the women in the allergic families cohort had less than
a high school education, whereas nationwide in 2004,
36% of births were to unmarried women and 78% of
women who gave birth had completed 12 or more years
of school [44]. Nationally, about 10% of U.S. women
report smoking during pregnancy [44]; the rates are
slightly higher for both URECA cohorts.
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Screening, eligibility, and enrollment frequencies for the allergic family and non-allergic family URECA cohortsFigure 2
Screening, eligibility, and enrollment frequencies for the allergic family and non-allergic family URECA 
cohorts.
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Table 3: Characteristics of the mothers and fathers of children enrolled in the allergic and non-allergic families cohorts (as reported by 
the mother at the prenatal interview)
Allergic Families Non-allergic Families
Characteristic n % n %
557 100.0 49 100.0
Mother's age in years at child's birth
13–17 41 7.4 3 6.1
18–19 85 15.3 10 20.4
20–24 204 36.6 13 26.5
25–29 119 21.4 14 28.6
30–34 62 11.1 4 8.2
35–39 40 7.2 5 10.2
40–42 6 1.1 0 0.0
Race or ethnicity of mother*
Hispanic of any race 107 19.4 9 18.4
Black alone 390 70.9 39 79.6
White alone 22 4.0 0 0.0
More than one race 20 3.6 1 2.0
All others 11 2.0 0 0.0
Missing 7 -- 0 --
Race or ethnicity of father†
Hispanic of any race 99 18.0 10 20.4
Black alone 407 74.1 38 77.6
White alone 14 2.6 0 0.0
More than one race 20 3.6 0 0.0
All others 9 1.6 1 2.0
Missing 8 -- 0 --
Mother's education
Less than high school 231 42.0 14 28.6
High school 183 33.3 23 46.9
More than high school 136 24.7 12 24.5
Missing 7 -- 0 --
Mother's marital status at prenatal visit
Married 72 13.1 8 16.3
Not married 478 86.9 41 83.7
Missing 7 -- 0 --
Mother smoked during pregnancy 97 17.6 6 12.2
Adult in the family with a regular job 366 66.7 38 77.6
Household annual income < $15,000 353 68.4 29 67.4
Number of previous live births
0 220 39.5 17 34.7
1 147 26.4 19 38.8
2 96 17.2 5 10.2
t 3 94 16.9 8 16.3
Number of children in household < 5 years old
0 277 50.4 23 46.9
1 180 32.7 20 40.8
2 60 10.9 5 10.2
t 3 33 6.0 1 2.0
Missing 7 -- 0 --
Number of years at current address
< 1 185 33.6 20 40.8
1–2 142 25.8 15 30.6
3–4 72 13.1 6 12.2
5–9 72 13.1 0 0.0
t 10 79 14.4 8 16.3
Missing 7 -- 0 --
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The URECA study excluded children born earlier than 34
weeks of gestation, to avoid the problem of trying to sep-
arate asthma from chronic lung disease associated with
prematurity. In spite of the exclusion of very premature
babies, the average birthweight of the URECA children
(Table 4) was less than the national average of 3316 grams
for singleton births in the U.S. in 2004 [44]. This is likely
related to the low socioeconomic status and overrepresen-
tation of minorities in the URECA population. The low
birthweight rate for black mothers in the U.S. is twice as
high as for non-Hispanic white mothers, even for term
births [44]. Other characteristics of the URECA children
were similar to children in the U.S. a whole. For example,
the percentage of U.S. children with 5-minute Apgar
scores of 9 or 10 was 88.8% in 2004 compared to 89.6%
and 93.9% of the URECA children in the allergic and non-
allergic families cohorts, respectively [44]. Furthermore,
the percentage of U.S. children born by Cesarean section
was 29.1% in 2004 compared to 31.2% and 28.5% of the
* Determined by the open-ended question, "How would you describe your race, nationality, or ethnic background?"
† Determined by the open-ended question, "How would you describe the race, nationality, or ethnic background of the father of this baby?"
Table 3: Characteristics of the mothers and fathers of children enrolled in the allergic and non-allergic families cohorts (as reported by 
the mother at the prenatal interview) (Continued)
Table 4: Characteristics of the newborns enrolled in the allergic and non-allergic families cohorts
Allergic Families Non-Allergic Families
Characteristic n % N %
560 100.0 49 100.0
Race or ethnicity*
Hispanic of any race 115 20.8 10 20.4
Black alone 386 69.8 37 75.5
White alone 7 1.3 0 0.0
More than one race 38 6.9 2 4.1
All others 7 1.3 0 0.0
Missing 7 -- 0 --
Sex
Male 287 51.2 25 51.0
Female 273 48.8 24 49.0
Gestational age in weeks
34 9 1.6 0 0.0
35 13 2.3 0 0.0
36 25 4.5 1 2.0
37 61 10.9 6 12.2
38 100 17.9 10 20.4
39 173 30.9 15 30.6
40 118 21.1 11 22.4
41 59 10.5 6 12.2
42 2 0.4 0 0.0
Type of delivery
Spontaneous vaginal 342 61.1 31 63.3
Assisted vaginal 43 7.7 4 8.2
Elective c-section 68 12.1 12 24.5
Non-elective c-section 107 19.1 2 4.0
Breastfed at birth 289 57.2 29 61.7
Breastfeeding at 3 mos. 121 24.0 13 27.7
Household tobacco smoke exposure at 3 mos. 263 58.7 23 56.1
Continuous measures Mean SD Mean SD
Gestational age (weeks) 38.7 1.5 39.0 1.3
Birthweight (grams) 3236.8 514.4 3211.8 503.9
Length (cm) 50.1 2.5 49.9 2.7
Head circumference (cm) 33.6 1.6 33.3 2.2
5-minute Apgar score 8.9 0.5 8.9 0.5
*Determined by the open-ended question posed to the mother, "How would you describe the race, nationality, or ethnic background of your 
baby?"
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URECA children in the allergic and non-allergic families
cohorts, respectively [44].
Children in the URECA cohorts are at increased risk of
developing asthma from a number of perspectives. Both
minority and low socioeconomic status are associated
with an increased risk of asthma, which likely is a conse-
quence of harmful environmental exposures. The risk of
asthma is further increased for the allergic families cohort
by having at least one parent with allergic disease [45].
Several scientific studies indicate that children of atopic
parents can have skewed immunologic responses in early
childhood, even in the absence of clinical manifestations
of atopy [36,46,47]. It is possible that this skewing reflects
an increased likelihood for allergy and asthma later in
childhood. Furthermore, children of atopic and non-
atopic parents could differ in other ways, including the
number and severity of viral respiratory infections or envi-
ronmental exposures to microbes, allergens, or indoor
pollutants. The two birth cohorts will allow exploration of
differences between children of atopic and non-atopic
parents.
Strengths of the URECA study include its unique popula-
tion, large sample size, and prospective collection of data
related to urban environmental factors, immune develop-
ment, and atopic outcomes. Challenges include working
with families that may have inconsistent access to trans-
portation and telephone service and may relocate during
the study period. In addition, the multicenter nature of
this study has required careful attention to the develop-
ment of data collection and laboratory procedures that
can be standardized across multiple centers. Despite the
challenges, 87% of the enrolled families are still active in
the study.
The study is a high-risk cohort, and findings must be inter-
preted accordingly. Comparisons with the non-atopic
group should provide valuable insights into the relation-
ship of study findings to the general population. In addi-
tion, the study focuses on the maternal/child axis, and
there is limited, voluntary, participation of fathers. The
majority of the mothers in the study are single, and we felt
that requiring paternal involvement would severely
restrict study enrollment. A final limitation of the study is
that the inclusion of detailed immunologic measure-
ments and viral sampling limited the feasible sample size,
and as a result the power for genetic analysis is modest.
Nonetheless, the longitudinal immunologic and asthma
phenotyping will provide precise outcomes for analysis.
Conclusion
A number of environmental and lifestyle factors that are
increased in the inner city are known to be injurious to
lung health in early childhood. The overall goal of URECA
is to develop a better understanding of how specific urban
exposures affect immune development to promote
wheezing illnesses and asthma, so that in the future, an
evidence-based approach to the prevention of these com-
mon disorders can be taken.
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